About

About Aicuris US, Inc. “AiCuris is meeting the needs of the growing population of immunocompromised people who require precise therapies to effectively treat infection. Our flagship product, PREVYMIS®, marketed by our partner MSD, treats CMV in a defined group of transplant recipients. Our pivotal phase 3 candidate pritelivir aims to address recurrent and resistant HSV infections in a broad population of patients with weakened immune systems. For immunocompromised people, an otherwise manageable infection can mean life or death. At Aicuris, we combine deep scientific knowledge with a patient-first mindset, striving to redefine the future of infection prevention and treatment.